Famotidine

Zollinger-Ellison Syndrome, Curling Ulcer, Indigestion + 21 more

Treatment

4 FDA approvals

20 Active Studies for Famotidine

What is Famotidine

Famotidine

The Generic name of this drug

Treatment Summary

Famotidine is a medication used to reduce the production of stomach acid. It is typically used to treat gastrointestinal conditions caused by excess stomach acid, such as gastric ulcers and GERD. It is more potent than other H2 receptor antagonists, meaning it is more effective at reducing stomach acid. It is available in oral and intravenous forms, with the latter being used in hospital settings.

Pepcid

is the brand name

image of different drug pills on a surface

Famotidine Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Pepcid

Famotidine

1986

623

Approved as Treatment by the FDA

Famotidine, also called Pepcid, is approved by the FDA for 4 uses which include Heartburn and Heartburn .

Heartburn

Heartburn

prophylaxis of Heartburn

Heartburn

Effectiveness

How Famotidine Affects Patients

Famotidine helps reduce the amount of acid in your stomach, as well as the amount of pepsin and gastric secretions. It works quickly, usually within one hour, and lasts for up to 12 hours. The more of this drug you take, the longer it will last and the more it will reduce acid production.

How Famotidine works in the body

Histamine is a hormone that causes the stomach to produce acid. It is released by cells in the stomach and also stimulated by acetylcholine and gastrin, a peptide hormone. When gastrin binds to certain receptors, it triggers the release of histamine, which then binds to other receptors on the stomach and signals it to make more acid. Famotidine works by blocking the effects of histamine, which prevents the stomach from making too much acid. This can help to treat conditions like ulcers, which are caused by too much acid in the stomach.

When to interrupt dosage

The measure of Famotidine is reliant upon the distinguished condition, including Heartburn, Heartburn and Pathological Conditions, Anatomical. The measurement of dosage can be seen in the table beneath, contingent upon the technique of delivery (e.g. Tablet, film coated - Oral or Oral).

Condition

Dosage

Administration

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Collagen Diseases

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Erosive Esophagitis

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Obesity

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Zollinger-Ellison Syndrome

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Stress Ulcers

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Pain

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Gastric ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Multiple Endocrine Neoplasia

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Critical Illness

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Spasm

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Pathological Conditions, Anatomical

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Helicobacter Pylori Infection

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Osteoarthritis

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Chronic Back Pain

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

prophylaxis of Stress Ulcers

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Heartburn

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Duodenal Ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Stomach Ulcer

, 10.0 mg/mL, 10.0 mg, 40.0 mg, 2.0 mg/mL, 20.0 mg, 40.0 mg/mL, 26.6 mg

, Intravenous, Injection, solution, Injection, solution - Intravenous, Tablet - Oral, Oral, Tablet, Tablet, chewable, Tablet, chewable - Oral, Tablet, film coated, Tablet, film coated - Oral, Powder, for suspension, Powder, for suspension - Oral, Injection, Injection - Intravenous, Tablet, coated - Oral, Tablet, coated, For suspension, For suspension - Oral, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release, Solution, Solution - Intravenous, Powder, for solution - Oral, Powder, for solution, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Injection, solution, concentrate - Intravenous, Injection, solution, concentrate

Warnings

Famotidine Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Famotidine.

Common Famotidine Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The excretion of Abemaciclib can be decreased when combined with Famotidine.

Acenocoumarol

Major

The metabolism of Acenocoumarol can be decreased when combined with Famotidine.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Famotidine.

Anagrelide

Major

The metabolism of Anagrelide can be decreased when combined with Famotidine.

Atazanavir

Major

Famotidine can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.

Famotidine Toxicity & Overdose Risk

The most toxic dose of Famotidine for rats when taken orally is 4049 mg/kg, and 4686 mg/kg for mice. When taking it subcutaneously, the most toxic dose for rats and mice is 800 mg/kg. The lowest reported toxic dose for humans is 4 mg/kg. Symptoms of Famotidine overdose are similar to the side effects of taking recommended doses, and should be treated with supportive and symptomatic care. Unabsorbed drug should be removed from the gastrointestinal tract, and the patient should be monitored carefully. Hemodialysis can be used to remove the drug from the body, although there

image of a doctor in a lab doing drug, clinical research

Famotidine Novel Uses: Which Conditions Have a Clinical Trial Featuring Famotidine?

45 ongoing investigations are analyzing the potential of Famotidine to alleviate Collagen Diseases, Gastric Acid Dyspepsia and Muscle Spasms.

Condition

Clinical Trials

Trial Phases

Postoperative Pain

19 Actively Recruiting

Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable

Chronic Back Pain

5 Actively Recruiting

Not Applicable

Collagen Diseases

0 Actively Recruiting

Gastric ulcer

0 Actively Recruiting

Critical Illness

0 Actively Recruiting

Gastritis

0 Actively Recruiting

Duodenal Ulcer

0 Actively Recruiting

Zollinger-Ellison Syndrome

0 Actively Recruiting

Curling Ulcer

0 Actively Recruiting

Indigestion

6 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Heartburn

2 Actively Recruiting

Phase 3, Not Applicable

Multiple Endocrine Neoplasia

0 Actively Recruiting

Stress Ulcers

0 Actively Recruiting

Heartburn

0 Actively Recruiting

Spasm

0 Actively Recruiting

Erosive Esophagitis

2 Actively Recruiting

Phase 2, Phase 3

Obesity

0 Actively Recruiting

Pathological Conditions, Anatomical

3 Actively Recruiting

Phase 3, Not Applicable, Phase 2

Osteoarthritis

0 Actively Recruiting

prophylaxis of Stress Ulcers

0 Actively Recruiting

Famotidine Reviews: What are patients saying about Famotidine?

5

Patient Review

3/11/2016

Famotidine for Excessive Production of Stomach Acid

This drug was really great in getting rid of stomach gurgling and bad breath. Once things were under control, I found that I could reduce the dosage without losing any effectiveness.

5

Patient Review

10/14/2017

Famotidine for Heartburn

Famotidine is great for when you know you're going to need something stronger than Tums or Rolaids.

5

Patient Review

4/21/2018

Famotidine for Treatment to Prevent Heartburn

Famotidine has been a total life-saver for me. I had given up hope that there was anything that could help my chronic heartburn, but this medication finally did the trick.

5

Patient Review

3/28/2020

Famotidine for Excessive Production of Stomach Acid

I'd never needed this medication before, but I'm so glad it exists! It works great. Within half an hour, all the gas and pressure was gone.

5

Patient Review

8/5/2021

Famotidine for Excessive Production of Stomach Acid

I was pregnant with twins and this treatment really helped me with my heartburn.

4.3

Patient Review

3/13/2017

Famotidine for Inflammation of the Esophagus with Erosion

I've been taking this medication for a few months now. I would prefer if it came in a lower dose or if I could take it just once a day because the current dosing schedule gives me pretty bad diarrhea. The dry skin is also unpleasant, but that's to be expected with this kind of medication. All things considered though, it has effectively healed my esophagus and I'm generally happy with it.

4.3

Patient Review

9/10/2017

Famotidine for Heartburn

Famotidine is great for me. I notice a difference within an hour, and it's affordable too, which is awesome.

4.3

Patient Review

5/19/2022

Famotidine for Treatment to Prevent Heartburn

I've always had relatively minor but frequent heartburn. Earlier this year I had three incidents where I belched up stomach contents. 20mg famotidine once a day has been great for that. No heartburn unless I eat something acidic late in the day. And in those cases it's mild. Downside seems to be excess gas and diarrhea that I hope eventually stops; however, this is still an improvement compared to my previous condition.

4.3

Patient Review

5/17/2016

Famotidine for Bleeding from Stomach, Esophagus or Duodenum

This treatment is effective.

3.7

Patient Review

7/6/2018

Famotidine for Excessive Production of Stomach Acid

I've been taking this medication for three days now to help with my Gurd. I was taking pantopazole, which also worked well, but my doctor wanted me to wean off of it because of the side effects. The first thing I noticed is the diarrhea! I hope it goes away soon or else I'll have to find another drug that works.

3.7

Patient Review

12/24/2020

Famotidine for Inflammation of Esophagus from Backflow of Stomach Acid

While it's not perfect, this treatment is still better than nothing.

2.7

Patient Review

12/2/2016

Famotidine for Heartburn

I didn't see any benefits from this

2.3

Patient Review

7/21/2022

Famotidine for Heartburn

While this medicine did alleviate my heartburn, it came with a host of other problems like muscle aches, diarrhea, nausea, and fatigue. I initially thought I had contracted a virus but after doing some research realized that these were all common side effects of the medication.

2

Patient Review

11/21/2021

Famotidine for Inflammation of Esophagus from Backflow of Stomach Acid

Unfortunately, this did not work for my acid reflux.

1.7

Patient Review

2/14/2017

Famotidine for Stomach Ulcer

Unfortunately, this medication didn't do anything to stop my stomach pain. If anything, it made it worse by giving me diarrhea.

1.3

Patient Review

7/1/2021

Famotidine for Heartburn

I had terrible experiences with this treatment and would not recommend it to anyone. Woke me up in the middle of the night with heartburn that no amount of Tums or Alka Seltzer could touch. Also suffered from sore gums, nightmares, and headaches.

1.3

Patient Review

7/7/2022

Famotidine for Inflammation of Esophagus from Backflow of Stomach Acid

Does anyone have any suggestions for treating esophagitis? The burning and shortness of breath is becoming unbearable and I want to get back to living a normal life.

1

Patient Review

9/13/2022

Famotidine for Excessive Production of Stomach Acid

Unfortunately, this medication caused me a lot of pain and discomfort in my stomach area. It made me very sick and I would not recommend it to others.

1

Patient Review

8/2/2021

Famotidine for Stomach Ulcer

If you have IBS, avoid this drug at all cost! It made my symptoms so much worse and was honestly just terrible.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about famotidine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any side effects to taking famotidine?

"The side effects of Famotidine can include confusion, hallucinations, agitation, lack of energy, a seizure, fast or pounding heartbeats, sudden dizziness, unexplained muscle pain, tenderness, or weakness."

Answered by AI

Why is famotidine taken off the market?

"The FDA has determined that the drug PEPCID (famotidine) was not withdrawn from sale for reasons of safety or effectiveness."

Answered by AI

What is a famotidine used for?

"Paraphrasing:

Famotidine is a medication used to treat stomach ulcers, heartburn, and gastroesophageal reflux disease (GERD). GERD is a condition in which acid from the stomach rises into the esophagus, causing irritation."

Answered by AI

Is it OK to take famotidine every day?

"Do not take more than the recommended dosage of over-the-counter famotidine. Do not take it for longer than the recommended time period unless your doctor tells you that it is okay."

Answered by AI

Clinical Trials for Famotidine

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of University Center for Ambulatory Surgery in Somerset, United States.

Infusion Pump for Postoperative Pain

18+
All Sexes
Somerset, NJ

This study will be a pragmatic, prospective cluster randomized trial, where clusters will formed based on sequential 2 week time increments across the study recruitment period.. Patients 18 years or older undergoing ACL reconstruction, open shoulder labrum or rotator cuff surgery, arthroscopic rotator cuff repair, proximal or distal patellar realignment surgery, open knee arthrotomy cases (i.e. inside out meniscus repair, osteochondral allograft transplantation (OCA), meniscal allograft transplantation (MAT)) at University Center for Ambulatory Surgery, LLC (UOA) will be reviewed for eligibility. Once identified, potential study subjects will be asked whether they are interested in participating in the project. If the patient agrees, the subject will be given the informed consent to read and sign. Objectives: The primary objective is to compare the effectiveness of postoperative infusion pain pump versus preoperative nerve block in reducing visual analog pain scores/numerical pain rating scale (VAS/NPRS) in the postoperative period. The second objective is to evaluate the requirement of narcotic and non-narcotic analgesic medications between the two groups. Hypotheses: Use of continuous infusion pain pump or single shot peripheral block will result in similar post-operative pain control after outpatient sports medicine surgical cases.

Phase 4
Recruiting

University Center for Ambulatory Surgery

Have you considered Famotidine clinical trials?

We made a collection of clinical trials featuring Famotidine, we think they might fit your search criteria.
Go to Trials
Image of Public Health Research Center: Clinical Exercise Research Center in Columbia, United States.

Pistachio Snacking for Obesity

25 - 45
All Sexes
Columbia, SC

The purpose of this study is to evaluate the effects of pistachio snacking on metabolic flexibility (at rest, during exercise, and in post-exercise recovery) in healthy overweight and obese adults. Secondary goals include evaluating effects on changes in diet quality, sleep characteristics, physical activity, and hormonal health in women. In randomized order, participants will complete four days of pistachio snacking and four days of normal dietary habits (control). For both conditions, primary outcomes of resting substrate metabolism, metabolic flexibility during exercise, and post-exercise substrate metabolism will be measured pre-post intervention via indirect calorimetry. Secondary outcome of diet quality (kcal, carb, fat, protein) will be measured pre-post intervention via diet log. Exploratory outcomes of daily physical activity (steps, intensity), nightly sleep characteristics (quantity, quality, latency, efficiency), and daytime sleepiness and hunger.

Recruiting
Has No Placebo

Public Health Research Center: Clinical Exercise Research Center

Katie R Hirsch, PhD

Have you considered Famotidine clinical trials?

We made a collection of clinical trials featuring Famotidine, we think they might fit your search criteria.
Go to Trials
Image of Villanova University in Villanova, United States.

BRAVE Intervention for Obesity Stigma

18 - 25
All Sexes
Villanova, PA

This randomized controlled trial will be a curriculum-embedded weight sensitivity training program. There will be two groups. The control group will receive the standard obesity lecture (SOL) and the intervention group will receive the BRAVE Intervention (BRAVE: Building Respect and Acceptance through Valuing Everybody); a Weight Bias Reduction (WBR) intervention. Both groups will have two simulation encounters with standardized patients who are living with obesity and the outcome will be to improve weight bias and increase weight sensitivity over one year. Participants will include second- and fourth-year nursing students. Two cohorts of nursing students will be recruited over two years during orientation for their NUR courses (n = 368); a combined total of 420 students are typically enrolled in these courses. Study participants will be randomized by 8-person simulation groups (clusters) to either the BRAVE intervention or SOL control group. They will then participate in the two simulation-based experiences and weight bias reduction education or standard obesity lecture, respectively, with a debriefing segment and educational components. To compare the efficacy of BRAVE groups to SOL groups in validated questionnaires will assess changing attitudes, beliefs, and clinical communication behaviors when comparing baseline to 3 months post-intervention, and one year after the intervention.

Waitlist Available
Behavior

Villanova University

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Local Restaurant Site in Bryan, United States.

Menu Labeling for Healthy Habits and Diet

18+
All Sexes
Bryan, TX

This study evaluates the impact of culturally tailored menu labeling interventions on psychosocial factors and ordering behavior among customers in two independently owned Hispanic restaurants in East-Central Texas. Participants will be exposed to one of three sequential menu conditions at each restaurant: (1) a standard menu without nutrition information, (2) a paper menu with bilingual nutrition labels, or (3) a digital menu app enhanced with Augmented Reality (AR) and Artificial Intelligence (AI) providing interactive nutrition guidance. The study will assess whether menu formats influence nutrition literacy, decision-making confidence, self-efficacy, attitudes, behavioral intentions, and actual ordering behavior. Data will be collected through surveys, purchase receipts, and app interaction logs.

Recruiting
Has No Placebo

Local Restaurant Site

Hyunjung Lee, PhD

Have you considered Famotidine clinical trials?

We made a collection of clinical trials featuring Famotidine, we think they might fit your search criteria.
Go to Trials